



**ASX RELEASE**  
**30 September 2016**

**ASX: NOX**

**Noxopharm  
Limited**

ABN 50 608 966  
123

**Registered Office:**  
Suite 1 Level 6  
50 Queen St  
Melbourne VIC  
3000  
Australia

**Board of  
Directors**  
**Mr Peter Marks**  
Chairman  
Non-Executive  
Director

**Dr Graham Kelly**  
Chief Executive  
Officer  
Managing Director

**Dr Ian Dixon**  
Non-Executive  
Director

**Amendment to Preliminary Final Report, reduction in loss for the period**

As a result of the recently completed Audit process the reported Loss for the period to 30 June 2016 has been reduced from \$1,542,655 to \$704,725.

This change is of a non-cash nature and amounts to \$837,930 accounting treatment of Options in accordance with the Share Based Payments accounting standard AASB2.

There is no change to the Assets or Net Assets for the Company or any other changes resulting from this amendment.

**About NOX66**

NOX66 is an innovative dosage formulation of idronoxil, a compound that down-regulates pro-survival mechanisms in cancer cells, including the cell's ability to establish and maintain a range of drug-resistance mechanisms. The primary target of idronoxil is tumour-specific external NADH oxidase 2 (or ENOX2), the protein responsible for maintaining the transmembrane electron potential in the cancer cell's plasma membrane. Loss of this potential inhibits the ability of the cancer cell to maintain a wide range of pro-survival mechanisms. NOX66 has been developed specifically to protect idronoxil from Phase 2 metabolism in the human body, and in so doing to increase the bio-availability of idronoxil to cancer cells.

**About Noxopharm**

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

**ENQUIRIES: Prue Kelly : [info@noxopharm.com](mailto:info@noxopharm.com) Phone: + 61 2 9144 2223**

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.